Related Experiment Videos
Lipid-bound sialic acid as a tumor marker
Annals of Clinical and Laboratory Science
|March 1, 1983
Summary
Elevated lipid bound sialic acid (LSA) levels are linked to various cancers. While not a standalone diagnostic tool, LSA may aid in monitoring cancer patients.
Area of Science:
- Biochemistry
- Oncology
- Clinical Chemistry
Background:
- Plasma/serum lipid bound sialic acid (LSA) concentrations are elevated in patients with malignant diseases.
- Previous research suggests LSA's potential as a biomarker for various cancers, including prostate, breast, lung, and leukemia.
Purpose of the Study:
- To evaluate the utility of lipid bound sialic acid (LSA) as a potential biomarker in oncology.
- To assess the diagnostic value of LSA in a range of malignant diseases.
Main Methods:
- Analysis of plasma/serum lipid bound sialic acid (LSA) concentrations.
- Comparison of LSA levels in cancer patients versus control groups (implied).
- Evaluation of LSA test performance characteristics (sensitivity and specificity).
Main Results:
- Significant elevations in LSA concentrations were observed in patients with various malignant diseases.
- LSA showed potential as a marker across multiple cancer types like prostate, breast, lung, colon, ovary, leukemia, lymphoma, Hodgkin's disease, and melanoma.
- The LSA test demonstrated limitations in sensitivity and specificity for routine cancer detection.
Conclusions:
- Lipid bound sialic acid (LSA) elevations are associated with malignancy.
- LSA is not sufficiently sensitive or specific for routine cancer diagnosis.
- LSA may serve as a valuable adjunct in the clinical management and evaluation of cancer patients.